Chinese General Practice ›› 2023, Vol. 26 ›› Issue (27): 3383-3387.DOI: 10.12114/j.issn.1007-9572.2023.0034
• Article • Previous Articles Next Articles
Received:
2022-11-01
Revised:
2023-02-25
Published:
2023-09-20
Online:
2023-03-23
Contact:
GAO Chuanyu
通讯作者:
高传玉
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0034
组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 男性〔例(%)〕 | BMI≥28 kg/m2 〔例(%)〕 | 高血压史〔例(%)〕 | 糖尿病史〔例(%)〕 | 吸烟史〔例(%)〕 | 他汀治疗史〔例(%)〕 | 冠心病家族史〔例(%)〕 | AMI史〔例(%)〕 | 血运重建史〔例(%)〕 |
---|---|---|---|---|---|---|---|---|---|---|---|
血脂达标组 | 84 | 41(38,43) | 78(92.9) | 47(56.0) | 46(54.8) | 37(44.1) | 62(73.8) | 44(52.4) | 18(21.4) | 32(38.1) | 8(9.5) |
血脂未达标组 | 361 | 41(37,43) | 341(94.5) | 164(45.4) | 181(50.1) | 109(30.2) | 236(65.4) | 181(50.1) | 83(23.0) | 89(24.7) | 62(17.2) |
χ2(Z)值 | -0.094a | 0.318 | 3.026 | 0.583 | 5.933 | 2.192 | 0.137 | 0.095 | 6.219 | 3.009 | |
P值 | 0.925 | 0.573 | 0.082 | 0.445 | 0.015 | 0.139 | 0.711 | 0.758 | 0.013 | 0.083 | |
组别 | ABCB1基因检测〔例(%)〕 | SLCO1B1基因检测〔例(%)〕 | 治疗方案〔例(%)〕 | TC 〔M(P25,P75),mmol/L〕 | TG 〔M(P25,P75),mmol/L〕 | 基线LDL-C 〔M(P25,P75),mmol/L〕 | |||||
药物治疗 | 介入治疗 | 冠状动脉搭桥治疗 | |||||||||
血脂达标组 | 68(81.0) | 60(71.4) | 13(15.5) | 68(81.0) | 3(3.5) | 3.94(3.28,4.53) | 1.92(1.38,2.93) | 2.81(2.38,3.32) | |||
血脂未达标组 | 232(64.3) | 196(54.3) | 53(14.7) | 273(75.6) | 35(9.7) | 3.50(2.91,4.34) | 1.63(1.17,2.46) | 2.47(1.88,3.28) | |||
χ2(Z)值 | 8.637 | 8.189 | 3.274 | -2.525a | -2.761a | -3.054a | |||||
P值 | 0.003 | 0.004 | 0.195 | 0.012 | 0.006 | 0.002 | |||||
组别 | HDL-C 〔M(P25,P75),mmol/L〕 | 非HDL-C 〔M(P25,P75),mmol/L〕 | 降脂方案〔例(%)〕 | 随访时间〔M(P25,P75),月〕 | |||||||
低强度他汀 | 中等强度他汀 | 高强度他汀 | 他汀联合依折麦布 | 他汀联合依洛尤单抗 | |||||||
血脂达标组 | 0.89(0.78,0.97) | 3.10(2.42,3.55) | 0 | 51(60.7)b | 5(6.0) | 4(4.7) | 24(28.6)b | 6(2,11) | |||
血脂未达标组 | 0.85(0.75,1.01) | 2.65(1.96,3.52) | 4(1.1) | 324(89.8) | 18(5.0) | 10(2.7) | 5(1.4) | 7(3,12) | |||
χ2(Z)值 | -0.612a | -2.475a | 64.240 | -1.183a | |||||||
P值 | 0.540 | 0.013 | <0.001 | 0.237 |
Table 1 Comparison of baseline data between two groups
组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 男性〔例(%)〕 | BMI≥28 kg/m2 〔例(%)〕 | 高血压史〔例(%)〕 | 糖尿病史〔例(%)〕 | 吸烟史〔例(%)〕 | 他汀治疗史〔例(%)〕 | 冠心病家族史〔例(%)〕 | AMI史〔例(%)〕 | 血运重建史〔例(%)〕 |
---|---|---|---|---|---|---|---|---|---|---|---|
血脂达标组 | 84 | 41(38,43) | 78(92.9) | 47(56.0) | 46(54.8) | 37(44.1) | 62(73.8) | 44(52.4) | 18(21.4) | 32(38.1) | 8(9.5) |
血脂未达标组 | 361 | 41(37,43) | 341(94.5) | 164(45.4) | 181(50.1) | 109(30.2) | 236(65.4) | 181(50.1) | 83(23.0) | 89(24.7) | 62(17.2) |
χ2(Z)值 | -0.094a | 0.318 | 3.026 | 0.583 | 5.933 | 2.192 | 0.137 | 0.095 | 6.219 | 3.009 | |
P值 | 0.925 | 0.573 | 0.082 | 0.445 | 0.015 | 0.139 | 0.711 | 0.758 | 0.013 | 0.083 | |
组别 | ABCB1基因检测〔例(%)〕 | SLCO1B1基因检测〔例(%)〕 | 治疗方案〔例(%)〕 | TC 〔M(P25,P75),mmol/L〕 | TG 〔M(P25,P75),mmol/L〕 | 基线LDL-C 〔M(P25,P75),mmol/L〕 | |||||
药物治疗 | 介入治疗 | 冠状动脉搭桥治疗 | |||||||||
血脂达标组 | 68(81.0) | 60(71.4) | 13(15.5) | 68(81.0) | 3(3.5) | 3.94(3.28,4.53) | 1.92(1.38,2.93) | 2.81(2.38,3.32) | |||
血脂未达标组 | 232(64.3) | 196(54.3) | 53(14.7) | 273(75.6) | 35(9.7) | 3.50(2.91,4.34) | 1.63(1.17,2.46) | 2.47(1.88,3.28) | |||
χ2(Z)值 | 8.637 | 8.189 | 3.274 | -2.525a | -2.761a | -3.054a | |||||
P值 | 0.003 | 0.004 | 0.195 | 0.012 | 0.006 | 0.002 | |||||
组别 | HDL-C 〔M(P25,P75),mmol/L〕 | 非HDL-C 〔M(P25,P75),mmol/L〕 | 降脂方案〔例(%)〕 | 随访时间〔M(P25,P75),月〕 | |||||||
低强度他汀 | 中等强度他汀 | 高强度他汀 | 他汀联合依折麦布 | 他汀联合依洛尤单抗 | |||||||
血脂达标组 | 0.89(0.78,0.97) | 3.10(2.42,3.55) | 0 | 51(60.7)b | 5(6.0) | 4(4.7) | 24(28.6)b | 6(2,11) | |||
血脂未达标组 | 0.85(0.75,1.01) | 2.65(1.96,3.52) | 4(1.1) | 324(89.8) | 18(5.0) | 10(2.7) | 5(1.4) | 7(3,12) | |||
χ2(Z)值 | -0.612a | -2.475a | 64.240 | -1.183a | |||||||
P值 | 0.540 | 0.013 | <0.001 | 0.237 |
指标 | rs值 | P值 |
---|---|---|
糖尿病史 | 0.115 | 0.015 |
AMI | 0.118 | 0.013 |
ABCB1基因检测 | 0.139 | 0.003 |
SLCO1B1基因检测 | 0.136 | 0.004 |
TC | 0.120 | 0.011 |
TG | 0.131 | 0.006 |
基线LDL-C | 0.145 | 0.002 |
非HDL-C | 0.117 | 0.013 |
中等强度他汀 | -0.312 | <0.001 |
他汀联合依洛尤单抗 | 0.431 | <0.001 |
Table 2 Correlation analysis between baseline data and lipid goal attainment
指标 | rs值 | P值 |
---|---|---|
糖尿病史 | 0.115 | 0.015 |
AMI | 0.118 | 0.013 |
ABCB1基因检测 | 0.139 | 0.003 |
SLCO1B1基因检测 | 0.136 | 0.004 |
TC | 0.120 | 0.011 |
TG | 0.131 | 0.006 |
基线LDL-C | 0.145 | 0.002 |
非HDL-C | 0.117 | 0.013 |
中等强度他汀 | -0.312 | <0.001 |
他汀联合依洛尤单抗 | 0.431 | <0.001 |
变量 | β | SE | Wald χ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
糖尿病史 | 0.599 | 0.248 | 5.836 | 1.820 | (1.120,2.959) | 0.016 |
AMI | 0.632 | 0.256 | 6.101 | 1.881 | (1.139,3.105) | 0.014 |
ABCB1基因检测 | 0.860 | 0.299 | 8.285 | 2.363 | (1.316,4.244) | 0.004 |
SLCO1B1基因检测 | 0.744 | 0.264 | 7.968 | 2.105 | (1.255,3.528) | 0.005 |
TC | 0.161 | 0.101 | 2.519 | 1.174 | (0.963,1.432) | 0.113 |
TG | 0.021 | 0.058 | 0.136 | 1.022 | (0.912,1.145) | 0.712 |
基线LDL-C | 0.165 | 0.100 | 2.732 | 1.180 | (0.970,1.435) | 0.098 |
非HDL-C | 0.163 | 0.104 | 2.489 | 1.177 | (0.961,1.442) | 0.115 |
中等强度他汀 | -1.735 | 0.283 | 37.595 | 0.176 | (0.101,0.307) | <0.001 |
他汀联合依洛尤单抗 | 3.349 | 0.511 | 42.954 | 28.480 | (10.461,77.539) | <0.001 |
Table 3 Univariate Logistic regression analysis of influencing factors of lipid goal attainment
变量 | β | SE | Wald χ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
糖尿病史 | 0.599 | 0.248 | 5.836 | 1.820 | (1.120,2.959) | 0.016 |
AMI | 0.632 | 0.256 | 6.101 | 1.881 | (1.139,3.105) | 0.014 |
ABCB1基因检测 | 0.860 | 0.299 | 8.285 | 2.363 | (1.316,4.244) | 0.004 |
SLCO1B1基因检测 | 0.744 | 0.264 | 7.968 | 2.105 | (1.255,3.528) | 0.005 |
TC | 0.161 | 0.101 | 2.519 | 1.174 | (0.963,1.432) | 0.113 |
TG | 0.021 | 0.058 | 0.136 | 1.022 | (0.912,1.145) | 0.712 |
基线LDL-C | 0.165 | 0.100 | 2.732 | 1.180 | (0.970,1.435) | 0.098 |
非HDL-C | 0.163 | 0.104 | 2.489 | 1.177 | (0.961,1.442) | 0.115 |
中等强度他汀 | -1.735 | 0.283 | 37.595 | 0.176 | (0.101,0.307) | <0.001 |
他汀联合依洛尤单抗 | 3.349 | 0.511 | 42.954 | 28.480 | (10.461,77.539) | <0.001 |
变量 | β | SE | Wald χ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
糖尿病史 | 0.591 | 0.277 | 4.543 | 1.806 | (1.049,3.110) | 0.033 |
AMI | 0.809 | 0.284 | 8.130 | 2.245 | (1.288,3.913) | 0.004 |
他汀联合依洛尤单抗 | 3.454 | 0.521 | 43.892 | 31.635 | (11.386,87.896) | <0.001 |
Table 4 Multivariate Logistic regression analysis of influencing factors of lipid goal attainment
变量 | β | SE | Wald χ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
糖尿病史 | 0.591 | 0.277 | 4.543 | 1.806 | (1.049,3.110) | 0.033 |
AMI | 0.809 | 0.284 | 8.130 | 2.245 | (1.288,3.913) | 0.004 |
他汀联合依洛尤单抗 | 3.454 | 0.521 | 43.892 | 31.635 | (11.386,87.896) | <0.001 |
[1] |
中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志,2022,37(6):553-578. DOI:10.3969/j.issn.1000-3614.2022.06.001
|
[2] |
|
[3] |
中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华心血管病杂志编辑委员会. 超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J]. 中华心血管病杂志,2020,48(4):280-286. DOI:10.3760/cma.j.cn112148-20200121-00036.
|
[4] |
中国医师协会急诊医师分会,国家卫健委能力建设与继续教育中心急诊学专家委员会,中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南(2019)[J]. 临床急诊杂志,2019,20(4):253-262. DOI:10.13201/j.issn.1009-5918.2019.04.001.
|
[5] |
滕浩波,高岩,郭远林,等. 我国成人冠心病患者中家族性高胆固醇血症检出率及治疗现状[J]. 中国循环杂志,2021,36(5):444-450. DOI:10.3969/j.issn.1000-3614.2021.05.006.
|
[6] |
|
[7] |
中华医学会心血管病学分会,中国康复医学会心脏预防与康复专业委员会,中国老年学和老年医学会心脏专业委员会,等. 中国心血管病一级预防指南[J]. 中华心血管病杂志,2020,48(12):1000-1038. DOI:10.3760/cma.j.cn112148-20201009-00796.
|
[8] |
|
[9] |
|
[10] |
CHOLESTEROL TREATMENT TRIALISTS'(CTT)COLLABORATION,
|
[11] |
|
[12] |
|
[13] |
|
[14] |
曾雨虹,刘静,刘军,等. 超高危ASCVD患者的界定标准对住院ACS患者降脂治疗需求的影响[J]. 中华心血管病杂志,2020,48(12):1039-1046. DOI:10.3760/cma.j.cn112148-20200710-00549.
|
[15] |
|
[16] |
南楠,左惠娟,周渊,等. 比较3种不同指南/共识评价极高风险或超高危动脉粥样硬化性心血管疾病危险分层和血脂达标率差异[J]. 中华内科杂志,2022,61(4):377-383. DOI:10.3760/cma.j.cn112138-20210529-00379.
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[1] | LIU Bingwei, WANG Jing, QIAO Xue, MU Silin, SHI Guangxi, LI Jingwei. Clinical Characteristics and Traditional Chinese Medicine of Hyperlipidemia in Estrogen Receptor Positive Breast Cancer Patients during Endocrine Therapy: a Real World Study [J]. Chinese General Practice, 2023, 26(36): 4558-4564. |
[2] | BAI Haiwei, MI Xiaokun, LIU Qingrui, ZHU Lin, WANG Yingnan, LIU Junyan, HAN Ying. Predictive Value of Serum Uric Acid in Perioperative Acute Ischemic Stroke in Patients with Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(36): 4545-4551. |
[3] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[4] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[5] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[6] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[7] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[8] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[9] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[10] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[11] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[12] | WANG Qiushi, LI Hongwei. The Predictive Value of CHA2DS2-VASc Score on Major Adverse Cardiovascular Events in Patients with Three Vessels or Left Main Diseases of Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(33): 4130-4136. |
[13] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[14] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[15] | GAO Dekang, WEI Shaohua, MA Xiaoming, DU Peng, XING Chungen, CAO Chun. Risk Factors for Loss of Skeletal Muscle Mass and Its Correlation with Complications after Major Hepatectomy for Liver Cancer [J]. Chinese General Practice, 2023, 26(32): 4031-4037. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||